0001193125-15-277670.txt : 20150819 0001193125-15-277670.hdr.sgml : 20150819 20150805071453 ACCESSION NUMBER: 0001193125-15-277670 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20150805 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20150805 DATE AS OF CHANGE: 20150805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CONCERT PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001367920 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36310 FILM NUMBER: 151027447 BUSINESS ADDRESS: STREET 1: 99 HAYDEN AVENUE STREET 2: SUITE 500 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-860-0045 MAIL ADDRESS: STREET 1: 99 HAYDEN AVENUE STREET 2: SUITE 500 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: CONCERT PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060628 8-K 1 d159101d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 5, 2015

 

 

Concert Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-36310   20-4839882

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

99 Hayden Avenue, Suite 500

Lexington, Massachusetts

  02421
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (781) 860-0045

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 2.02. Results of Operations and Financial Condition.

On August 5, 2015, Concert Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2015. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

The Exhibits to this Current Report on Form 8-K are listed in the Exhibit Index attached hereto.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      CONCERT PHARMACEUTICALS, INC.
    By:  

/s/ Roger D. Tung

Date: August 5, 2015       Roger D. Tung
     

President and Chief Executive Officer


EXHIBIT INDEX

 

Exhibit
No.
   Description
99.1    Press Release issued by Concert Pharmaceuticals, Inc., dated August 5, 2015.
EX-99.1 2 d159101dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO      NEWS RELEASE

For additional information contact:

Justine Koenigsberg (investors)

Concert Pharmaceuticals, Inc.

(781) 674-5284

ir@concertpharma.com

Kathryn Morris (media)

The Yates Network

(845) 635-9828

FOR IMMEDIATE RELEASE

Concert Pharmaceuticals Reports Second Quarter 2015 Financial Results and

Provides Company Update

Conference Call Scheduled Today at 8:30 a.m. EDT

Lexington, MA (August 5, 2015) — Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2015.

“We are pleased with the continued progress of our pipeline over the last quarter. In particular, we are encouraged by the progress Avanir has made with AVP-786 in 2015. We see a continued commitment by Avanir to broadly evaluate the potential of AVP-786 in multiple neurological disorders including Alzheimer’s agitation, schizophrenia and depression,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “In addition, we are focused on advancing Concert’s newest drug candidate CTP-656, our deuterium-modified ivacaftor, and we believe that with our strong balance sheet, Concert is well positioned to develop CTP-656 to provide patients with more choices and potentially better outcomes.”

Recent Business Highlights and Upcoming Milestones

 

    AVP-786 Phase 3 Planned for Agitation in Alzheimer’s Disease. In May 2015, Avanir Pharmaceuticals released their study design for two Phase 3 clinical trials evaluating AVP-786 for the treatment of agitation in patients with Alzheimer’s disease. The Phase 3 program is expected to begin in September 2015. Concert expects to achieve a $2 million milestone payment from Avanir upon the initiation of the Phase 3 clinical development of AVP-786.

 

    CTP-656 Phase 1 Trials for Cystic Fibrosis. In the second quarter of 2015, Concert selected CTP-656 as the candidate for further clinical development including single and multiple ascending dose Phase 1 trials. The single ascending dose Phase 1 trials have been completed. The multiple ascending dose Phase 1 trial is expected to commence in the fourth quarter of 2015.

 

    CTP-730 for Inflammatory Disease. The Phase 1 multiple ascending dose trial evaluating CTP-730 in healthy volunteers is expected to be completed in the third quarter of 2015. Upon completion of the Phase 1 evaluation, Concert expects to achieve an $8 million milestone from Celgene in the fourth quarter of 2015.

 

    $50 Million Payment from Auspex Pharmaceuticals. In June 2015, Concert received a one-time payment of $50.2 million from Auspex Pharmaceuticals, Inc. as a result of an existing patent assignment agreement between Concert and Auspex. Under the agreement, Concert became eligible to receive the payment due to a change of control of Auspex, which was acquired by Teva Pharmaceuticals Industries Ltd in May 2015.

 

- more -


Concert Reports Second Quarter 2015 Financial Results, Page 2

 

Second Quarter 2015 Financial Results

 

    Cash and Investment Position. Cash, cash equivalents and investments as of June 30, 2015, totaled $151.7 million as compared to $113.1 million as of March 31, 2015. In June 2015, Concert received a one-time payment of $50.2 million as a result of a patent assignment agreement with Auspex. Concert expects its cash, cash equivalents and investments as of June 30, 2015 are sufficient to fund the Company into 2018.

 

    Revenues. Revenue was $53.4 million for the quarter ended June 30, 2014, compared to $1.2 million for the corresponding quarter in 2014, which was primarily attributable to the payment of $50.2 million received from Auspex, as well as revenue recognized for services performed under our strategic collaborations with Celgene and Jazz Pharmaceuticals. 

 

    R&D Expenses. Research and development expenses were $8.4 million for the quarter ended June 30, 2015, compared to $6.2 million for the same period in 2014, an increase of $2.2 million. The increase in research and development expenses was primarily attributable to increased development expenses associated with CTP-656 and CTP-730.

 

    G&A Expenses. General and administrative expenses were $3.3 million for the quarter ended June 30, 2015, compared to $2.7 million for the same period in 2014, an increase of $0.5 million. The increase in general and administrative expenses was primarily related to compensation expenses, predominately non-cash stock-based compensation.

 

    Net Income (Loss). For the quarter ended June 30, 2015, net income was $41.0 million, or $1.89 per share, as compared to a net loss of $8.0 million, or $0.45 per share, for the quarter ended June 30, 2014. As a result of the Auspex payment, we expect to be profitable for the full year. We expect to have sufficient operating loss carryforwards available to offset our estimated ordinary taxable income for fiscal 2015. However, we recorded a tax provision of $0.6 million during the second quarter related to an alternative minimum tax obligation for 2015.

Conference Call and Webcast

The Company will host a conference call and webcast today at 8:30 a.m. EDT to provide an update on the company and discuss second quarter financial results. To access the conference call, please dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International) five minutes prior to the start time.

A live webcast of Concert’s presentation may be accessed in the Investors & Media section of the Company’s website at www.concertpharma.com. Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Concert’s website for three months.

 

- Financial Tables to Follow –


Concert Reports Second Quarter 2015 Financial Results, Page 3

 

Concert Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

 

  

  

  

     Three months ended
June 30,
    Six months ended
June 30,
 
     2015     2014     2015     2014  

Revenue:

        

License and research and development revenue

   $ 3,254      $ 1,235      $ 4,560      $ 2,848   

Other revenue

     50,155        —          50,155        —     
  

 

 

   

 

 

   

 

 

   

 

 

 

Total revenue

     53,409        1,235        54,715        2,848   
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating expenses:

        

Research and development

     8,420        6,243        15,364        11,837   

General and administrative

     3,299        2,718        6,532        5,256   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     11,719        8,961        21,896        17,093   
  

 

 

   

 

 

   

 

 

   

 

 

 

Income (Loss) from operations

     41,690        (7,726     32,819        (14,245

Interest and other expense, net

     (77     (264     (208     (695
  

 

 

   

 

 

   

 

 

   

 

 

 

Income (Loss) before income taxes

     41,613        (7,990     32,611        (14,940

Provision for income taxes

     567        —          567        —     
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss)

   $ 41,046      $ (7,990   $ 32,044      $ (14,940
  

 

 

   

 

 

   

 

 

   

 

 

 

Accretion on redeemable convertible preferred stock

     —          —          —          (55
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss) applicable to common stockholders

   $ 41,046      $ (7,990   $ 32,044      $ (14,995
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss) per share applicable to common stockholders—basic

   $ 1.89      $ (0.45   $ 1.58      $ (1.11
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss) per share applicable to common stockholders—diluted

   $ 1.80      $ (0.45   $ 1.50      $ (1.11
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted-average number of common shares used in net income (loss) per share applicable to common stockholders—basic

     21,762        17,937        20,252        13,495   
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted-average number of common shares used in net income (loss) per share applicable to common stockholders— diluted

     22,850        17,937        21,355        13,495   
  

 

 

   

 

 

   

 

 

   

 

 

 

Concert Pharmaceuticals, Inc.

Summary Balance Sheet Data

(in thousands)

 

     June 30,
2015
     December 31,
2014
 

Cash and cash equivalents

   $ 22,567       $ 13,396   

Investments, available for sale

     129,133         65,836   

Working capital

     142,812         63,102   

Total assets

     156,203         84,454   

Deferred revenue

     12,023         15,821   

Loan payable, net of discount

     2,929         7,101   

Total stockholders’ equity

   $ 135,744       $ 54,825   

 

- more -


Concert Reports Second Quarter 2015 Financial Results, Page 4

 

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy. The Company is developing a broad pipeline targeting CNS disorders, genetic diseases, renal disease, inflammatory diseases and cancer. For more information, please visit www.concertpharma.com.

Cautionary Note on Forward Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements about future milestone payments, our expectations for clinical development of our therapeutic candidates, including CTP-656 and AVP-786, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” section of our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission and in other filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release.

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.

###

GRAPHIC 3 g159101ex99_1pg001.jpg GRAPHIC begin 644 g159101ex99_1pg001.jpg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